5,399
Participants
Start Date
September 2, 2016
Primary Completion Date
January 31, 2019
Study Completion Date
September 30, 2027
F/TAF
200/25 mg tablet administered orally once daily
F/TDF
200/300 mg tablet administered orally once daily
F/TAF Placebo
Tablet administered orally once daily
F/TDF Placebo
Tablet administered orally once daily
Dublin
Vienna
Copenhagen
Hvidovre
Odense
Nice
Graz
Aarhus N
New York
New York
New York
Berlin
The Bronx
Berlin
Marseille
Philadelphia
Washington D.C.
Washington D.C.
Milan
Madrid
Huntersville
Atlanta
Atlanta
Atlanta
Macon
Pensacola
Orlando
Miami
Fort Lauderdale
Fort Lauderdale
West Palm Beach
Ft. Pierce
Vigo
Cleveland
Berkley
Detroit
Milwaukee
Minneapolis
Frankfurt
Chicago
Chicago
New Orleans
Paris
Dallas
Dallas
Paris
Houston
Austin
Aurora
Denver
Munich
Santa Fe
Las Vegas
Los Angeles
Los Angeles
Beverly Hills
Torrance
San Diego
Newport Beach
San Francisco
San Francisco
San Francisco
Oakland
Sacramento
Sacramento
Seattle
Seattle
New Haven
Boston
Springfield
Somers Point
Chapel Hill
Vancouver
Toronto
Montreal
Montreal
Montreal
Dublin
Roma
Amsterdam
Badalona
Barcelona
Soho
Whitechapel
Edinburgh
Brighton
Birmingham
London
London
London
London
London
Manchester
Lead Sponsor
Gilead Sciences
INDUSTRY